ライフサイエンスコーパス: did not differ between

1 ognitively normal individuals, neurodegeneration biomarkers did not differ between Abeta-N+ and Abeta+N+ cases.

2 mong alemtuzumab recipients than among rATG recipients, but did not differ between basiliximab and rATG recipients.

3 jective pleasantness ratings and skin conductance responses did not differ between behavioural variant frontotemporal dem

4 Total number of possible abnormalities did not differ between cases and controls.

5 Incidence of treatment-emergent adverse events did not differ between extended-pulsed fidaxomicin (121 [67%]

6 Microbial diversity measures did not differ between food sensitization and food allergy ca

7 e are indications that, before flooding, relative head size did not differ between future island and future mainland site

8 While glucose tolerance did not differ between genotypes at baseline it significantly

9 d preference in response to low-dose cocaine administration did not differ between genotypes.

10 Change in knowledge quiz score did not differ between groups (4.9% vs 0.6%; P = 0.084), desp

11 Childhood wasting did not differ between groups (OR 0.92, 95% CI 0.75-1.12), al

12 Although asthma control test did not differ between groups (P=.288), patients with paucigr

13 were percutaneous coronary interventions (94.2%), and this did not differ between groups (P=0.274).

14 PANSS positive score did not differ between groups after 12 weeks (adjusted mean c

15 The rate of stent thrombosis, a safety indicator, did not differ between groups and was low in both treatment g

16 and neurodevelopmental assessments at 18 to 24 months' PMA did not differ between groups.

17 The other antibodies did not differ between groups.

18 Rates of other adverse events did not differ between groups.

19 Age and basal glomerular filtration rate did not differ between groups.

20 Pulmonary complication rate did not differ between groups: 34.2% (OE) versus 35.6% (MIE)

21 were lower in elevated CO2 plots than in ambient plots, but did not differ between heat treatments.

22 hysical activity, 24-h glycemia, and 24-h insulin secretion did not differ between intervention days.

23 comes; (2) averaged between each patient's 2 eyes, outcomes did not differ between ISBCS and DSBCS patients.

24 expression levels of AROM, estrogen and androgen receptors did not differ between males and females and were not sex-spe

25 Sediment OC stocks did not differ between mangrove and saltmarsh habitats.

26 Mean skin temperature did not differ between menstrual phases (P >/= 0.13) but was

27 Risk factors for composite major morbidity did not differ between ODP and MIDP.

28 Though the number of partners did not differ between orphans and non-orphans, their types o

29 Treatment effects did not differ between participants with and without CKD (P v

30 B-6, and vitamin D (data collected from 2009 through 2010) did not differ between participants with gluten-related condi

31 Exercise performance did not differ between phases [EF: 257 (37), ML: 255 (43) kJ,

32 ctors though was due to starvation, and final removal rates did not differ between reactors inoculated with immobilized a

33 ling to participate in a biobank; willingness and attitudes did not differ between respondents in the three scenarios.

34 Overall mortality did not differ between rural and urban regions (1.44% vs 0.89

35 Oral food intake did not differ between the 2 groups.

36 Rates of myocardial infarction and stroke did not differ between the 2 groups.

37 Overall and serious adverse events did not differ between the flecainide and placebo arms.

38 The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19

39 ions performed by nonexperts (primarily residents, n = 290) did not differ between the groups (84.4% with video laryngosc

40 s adverse reactions were recorded and other safety measures did not differ between the groups, after allowing for missing

41 edness, nausea, sweating, and being restless or overactive) did not differ between the groups.

42 The quality of life index did not differ between the LC and SIOC groups at any time.

43 uximab group and 593 in the control group, overall survival did not differ between the treatment groups in the entire stu

44 edian overall survival in the intention-to-treat population did not differ between the treatment groups: 7.7 months (95%

45 r, changes in cardiac troponin T levels during the infusion did not differ between the two groups in the 55% of patients

46 verse events, mostly mild self-limited joint and back pain, did not differ between the yoga and PT groups.

47 oportion of patients alive and progression free at 24 weeks did not differ between those who received doxorubicin versus

48 CI 0.36-0.86; p=0.0071), although progression-free survival did not differ between treatment groups in this subgroup (0.6

49 The overall rate of serious adverse events did not differ between treatment groups, although some specif

50 stochemistry showed that HOXB13 gene and protein expression did not differ between tumour samples from variant and wild-t